Acenocoumarol
As of the edition of 20 October 2026, Acenocoumarol is a small molecule: marketed, first approved in 1955 (CH); acts on VKORC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Sintrom
- First approved
- 7 July 1955 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- MERUS LABS LUXCO II (LUXEMBOURG); 3 holders in all
- Registered trials
- 10, 1 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Cancer; Injuries; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | Q9BQB6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 0 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 2 | 0 | 0 | 0 |
| All trials | 10 |